Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: The Suita study

The Department of Atherosclerosis and Diabetes, National Cardiovascular Center, Osaka, Japan.
Endocrine Journal (Impact Factor: 2). 01/2010; 57(8):727-33. DOI: 10.1507/endocrj.K10E-067
Source: PubMed


The inverse association between plasma B-type natriuretic peptide (BNP) levels and body mass index (BMI) has been reported in Western populations. Here we analyzed the relationship between plasma BNP and obesity in a general urban Japanese population. We recruited 1,759 subjects without atrial fibrillation or history of ischemic heart disease aged 38-95 years (mean age +/- standard deviation 64.5 +/- 10.9 years, 56.1% women, mean BMI 22.8 +/- 3.1 kg/m(2)) from the participants in the Suita Study between August 2002 and December 2003. In multivariable regression analyses adjusted for age, systolic blood pressure, pulse rate, serum creatinine, left ventricular hypertrophy in ECG, the inverse relationships between BNP levels and BMI (kg/m(2)) was found in both sexes (both p<0.001). Multivariable-adjusted mean plasma BNP levels in the group of BMI<18.5, 18.5< or =BMI< 22, 22< or =BMI<25, and 25< or =BMI were 23.4, 17.9, 14.0 and 13.0 pg/mL, respectively (trend p<0.001). The negative association of body fat (percentage and mass), skin fold thickness, or waist circumference with BNP levels was observed the negative associations in both sexes (p<0.01). Among the obesity indices, body fat mass is most tightly associated with BNP. In conclusion, plasma BNP was inversely associated with obesity related markers such as body fat mass, skinfold thickness and waist circumferences after adjusted for relevant covariates in a Japanese population.

10 Reads
  • Source
    • "In this study, the average level (around 24.7 kg/m2) and distribution of BMI was comparable with other Asian studies [4], [13], but it was much lower in comparison with the western populations (around 28 kg/m2) [2], [3], [5], [7]. Of this study populations, 46% was normal weight (BMI<25 kg/m2), 51% overweight (BMI = 25–29.9 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background An inverse relationship between body mass index (BMI) and circulating levels of N-terminal proB-type natriuretic peptide (NT-proBNP) has been demonstrated in subjects with and without heart failure. Obesity also has been linked with increased incidence of atrial fibrillation (AF), but its influence on NT-proBNP concentrations in AF patients remains unclear. This study aimed to investigate the effect of BMI on NT-proBNP levels in AF patients without heart failure. Methods A total of 239 consecutive patients with AF undergoing catheter ablation were evaluated. Levels of NT-proBNP and clinical characteristics were compared in overweight or obese (BMI≥25 kg/m2) and normal weight (BMI<25 kg/m2) patients. Results Of 239 patients, 129 (54%) were overweight or obese. Overweight or obese patients were younger, more likely to have a history of nonparoxysmal AF, hypertension, and diabetes mellitus. Levels of NT-proBNP were significantly lower in overweight or obese than in normal weight subjects (P<0.05). The relationship of obesity and decreased NT-proBNP levels persisted in subgroup of hypertension, both gender and both age levels (≥65 yrs and <65 yrs).Multivariate linear regression identified BMI as an independent negative correlate of LogNT-proBNP level. Conclusions An inverse relationship between BMI and plasma NT-proBNP concentrations have been demonstrated in AF patients without heart failure. Overweight or obese patients with AF appear to have lower NT-proBNP levels than normal weight patients.
    PLoS ONE 08/2014; 9(8):e105249. DOI:10.1371/journal.pone.0105249 · 3.23 Impact Factor
  • Source
    • "Visceral fat accumulation correlated closely with systolic blood pressure [4], and is also related to the development of cardiac dysfunction [5]. However, circulating NPs levels are relatively low (within the normal limits) in obesity [6-11]. It has been suggested that obese subjects have a "natriuretic handicap", with a reduced NPs response to cardiac wall stress. "
    [Show abstract] [Hide abstract]
    ABSTRACT: B-type natriuretic peptide (BNP), a member of the natriuretic peptide family, is a cardiac-derived secretory hormone with natriuretic, diuretic, and vasorelaxant activities. Intraabdominal fat accumulation is associated with atherosclerotic cardiovascular diseases and cardiac dysfunction. Circulating BNP levels are relatively low (within the normal limits) in obesity and the metabolic syndrome. However, the relationship between plasma BNP levels and visceral fat accumulation in general population has not been reported. The present study analyzed the relationships between plasma BNP levels and various clinical variables, including insulin, visceral and subcutaneous fat area (VFA and SFA, respectively), in normal Japanese men. The study (Victor-J study) subjects were consecutive 500 Japanese male workers, who underwent a health checkup and were measured VFA and SFA by computed tomography. Age-adjusted simple linear regression analysis showed that log-BNP correlated positively with HDL-cholesterol, and negatively with VFA, log-immunoreactive insulin (IRI), log-triglyceride, and LDL-cholesterol, but not body mass index or SFA. Stepwise multiple regression analysis identified log-IRI and HDL-cholesterol as significant determinants of log-BNP. Subjects with IRI ≥5.5 μIU/mL had lower plasma BNP levels than those with IRI < 5.5 μIU/mL, irrespective of obesity (body mass index, cutoff value 25 kg/m2), visceral fat accumulation (VFA, cutoff value 100 cm2) and subcutaneous fat accumulation (SFA, cutoff value 128 cm2). Our study showed that hyperinsulinemia correlated with low levels of plasma BNP in general men, irrespective of fat distribution. UMIN 000004318.
    Cardiovascular Diabetology 03/2012; 11(1):22. DOI:10.1186/1475-2840-11-22 · 4.02 Impact Factor
  • Source
    • "Few population-based studies have investigated the relationship between BNP levels and these markers of fat mass [9] [34] [35]. Our results are consistent with the findings of an Asian cohort, which detected that these two components of fat mass were inversely related to BNP levels [34]. Conversely, the results of another large-based population cohort with individuals aged 30–65 years found only lean mass to be inversely related to BNP [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: B-type natriuretic peptide (BNP) is a diagnostic and prognostic tool in heart failure and also in Chagas disease, which is caused by the protozoan Trypanosoma cruzi and has cardiomyopathy as a main feature. BNP lipolytic actions and T. cruzi infection in the adipose tissue have been recently described. We aim to investigate the relationship between BNP and anthropometric measures and whether it is influenced by T. cruzi infection. We measured BNP, body mass index (BMI), waist circumference (WC), triceps skin-fold thickness (TSF) and performed serological, biochemical and electrocardiographic exams in 1398 subjects (37.5% infected with T. cruzi) in a community-dwelling elderly population in Bambui city, Brazil. Linear multivariate regression analysis was performed to investigate determinants of BNP levels. BNP levels were significantly (p<0.05) higher in T. cruzi-infected subjects than in the non-infected group (median=121 and 64pg/mL, respectively). BMI, WC and TSF in infected subjects were significantly lower than those in non-infected subjects (24.3 vs. 25.5kg/m2; 89.2 vs. 92.4cm; and 14.5 vs. 16.0mm, respectively). There was an inverse relationship between BNP levels and BMI (b=-0.018), WC (b=-0.005) and TSF (b=-0.193) levels. Infected and non-infected groups showed similar inverse relationships between BNP and BMI (b=-0.021 and b=-0.015, respectively). In conclusion, there was an inverse relationship between BNP levels and the anthropometric measures. Despite the actions in the adipose tissue, T. cruzi infection did not modify the associations between BNP and BMI, suggesting that body mass does not modify the accuracy of BNP in Chagas disease.
    Peptides 09/2011; 32(9):1787-92. DOI:10.1016/j.peptides.2011.08.013 · 2.62 Impact Factor
Show more